Microba Life Sciences Limited (MAP.AX)
ASX · AUD · Healthcare · Diagnostics & Research
A$0.035 (+0.00%) as of
Key statistics
- Market cap
- 25.10M
- Forward P/E
- -3.85
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.0330 – 0.1050
- Beta
- 2.10
- Revenue (TTM)
- 14.76M
- Profit margin
- -140.40%
- Analyst target
- A$0.08219
- Volume
- 17.07k
About Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, inflammatory bowel autoimmune diseases, oncology, and allergy. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Brisbane, QLD, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.